ANP Announces Major Research Collaboration with Big Bio-Pharma
Newark, DE – April 15, 2014
ANP Technologies, Inc., a world leader in developing and commercializing various nanobiotechnology-based products for applications related to therapeutic drug delivery, immunogenicity, biological drug development and testing, as well as biodefense, today announced a major research collaboration with one of the largest names in the Bio-Pharmaceutical industry.
The companies have executed a mutual non-disclosure/confidentiality agreement and have already begun work.
When asked to comment, ANP founder and president, Dr. Ray Yin noted, “We have been developing our platform for nano-delivery of poorly water soluble drugs for many years. It was perhaps ahead of its time when we first began working on it. The market now is becoming more educated as to the considerable potentialof nano-delivery technologies and the utility of nanotechnology for the re-formulation of poorly soluble drugs for both IV and oral drug delivery applications. The collaboration agreement sends that message to the market that even the largest players are sitting up and taking notice.”
Dr. Yin is referring to technology that he and his team developed close to ten years ago and have been building upon ever since. Since its inception in 2002, ANP has generated over 25 patents and has created a whole new class of detection and diagnostic products for immunogenicity testing and biodefense.
Additionally, ANP has been working with the University of Southern California’s Ming Hsieh Institute for Research on Engineering-Medicine for Cancer and Fulgent Therapeutics on its own pipeline of drug therapies for the treatment of certain types of cancer.
About ANP Technologies, Inc.
ANP Technologies, Inc. is a world leader in developing and commercializing various nano-biotechnology-based products for applications related to nanotherapeutics, immunogenicity, and biological drug development/testing.